Semaglutide
Semaglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Wegovy for weight management and Ozempic for type 2 diabetes, with significant effects on appetite control and blood sugar regulation.
Verified sources for Semaglutide
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Semaglutide
Activates GLP-1 receptors in the brain and pancreas to suppress appetite, delay gastric emptying, and improve glucose-dependent insulin secretion.
Activates GLP-1 receptors in hypothalamus and brainstem, stimulating satiety neurons (POMC/CART) and inhibiting hunger neurons (NPY/AgRP).
Reduces food cravings and hunger signals, supporting sustained calorie reduction.
Stimulates glucose-dependent insulin release from pancreatic β-cells, lowering blood sugar only when elevated, reducing hypoglycemia risk.
Suppresses glucagon secretion from pancreatic α-cells, lowering hepatic glucose output.
Slows food passage from stomach to small intestine, extending digestion time for prolonged satiety.
Reduces gastric emptying rate, contributing to reduced calorie intake per meal.
Improves endothelial function and reduces inflammation markers (proposed), which may provide cardiovascular protection.
May directly affect cardiac tissue through GLP-1 receptor activation (proposed)
Read Full Semaglutide Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss
Are Oral Peptides Here? Inside the Breakthrough and What's Next
Oral semaglutide just proved cardiovascular benefit, Eli Lilly cleared Phase 3, and a microneedle pill raised a billion dollars. Where the oral peptide era actually stands, and what it means for research peptides.
UPDATE: Retatrutide Clears First Phase 3 Diabetes Trial — 16.8% Weight Loss, 2.0% A1C Drop
Eli Lilly’s triple-agonist retatrutide delivered superior A1C and weight reductions in its first Phase 3 diabetes trial. Full TRANSCEND-T2D-1 breakdown.
Oral vs Injectable Peptides: Bioavailability and Effectiveness
Oral peptides face massive bioavailability barriers, but real exceptions exist. We break down the evidence for oral semaglutide, BPC-157, collagen peptides, and emerging delivery tech.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.